(Q46659724)

24 December 2017

title

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models (English)

1 reference

24 December 2017

1 reference

Jeffrey Eastham-Anderson

18

object named as

Jeffrey Eastham-Anderson

1 reference

24 December 2017

Napoleone Ferrara

20

object named as

Napoleone Ferrara

1 reference

24 December 2017

author name string

Mallika Singh

1

1 reference

24 December 2017

Suzana S Couto

2

1 reference

24 December 2017

William F Forrest

3

1 reference

24 December 2017

Anthony Lima

4

1 reference

24 December 2017

Jason H Cheng

5

1 reference

24 December 2017

Rafael Molina

6

1 reference

24 December 2017

Jason E Long

7

1 reference

24 December 2017

Patricia Hamilton

8

1 reference

24 December 2017

Angela McNutt

9

1 reference

24 December 2017

Ian Kasman

10

1 reference

24 December 2017

Michelle A Nannini

11

1 reference

24 December 2017

Hani Bou Reslan

12

1 reference

24 December 2017

Tim C Cao

13

1 reference

24 December 2017

Calvin C K Ho

14

1 reference

24 December 2017

Kai H Barck

15

1 reference

24 December 2017

Richard A D Carano

16

1 reference

24 December 2017

Oded Foreman

17

1 reference

24 December 2017

Adrian M Jubb

19

1 reference

24 December 2017

Leisa Johnson

21

1 reference

24 December 2017

publication date

28 June 2012

1 reference

24 December 2017

published in

Journal of Pathology

1 reference

24 December 2017

volume

227

1 reference

24 December 2017

page(s)

417-430

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

cites work

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

An overview of small-molecule inhibitors of VEGFR signaling

21 January 2018

1 reference

Vascular endothelial growth factor signaling pathways: therapeutic perspective

21 January 2018

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

Angiogenesis inhibitors: current strategies and future prospects

21 January 2018

1 reference

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

Adverse effects of anticancer agents that target the VEGF pathway

21 January 2018

1 reference

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

21 January 2018

1 reference

Pathways mediating VEGF-independent tumor angiogenesis

21 January 2018

1 reference

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

21 January 2018

1 reference

The mighty mouse: genetically engineered mouse models in cancer drug development

21 January 2018

1 reference

Using genetically engineered mouse models of cancer to aid drug development: an industry perspective

21 January 2018

1 reference

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

21 January 2018

1 reference

Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy

21 January 2018

1 reference

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis

21 January 2018

1 reference

The molecular pathogenesis of small cell lung cancer

21 January 2018

1 reference

Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study

21 January 2018

1 reference

Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma

21 January 2018

1 reference

Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium

21 January 2018

1 reference

21 January 2018

1 reference

Examining the safety profile of angiogenesis inhibitors: implications for clinical practice

21 January 2018

1 reference

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

21 January 2018

1 reference

Glioblastoma stem-like cells give rise to tumour endothelium.

21 January 2018

1 reference

EMT and dissemination precede pancreatic tumor formation

21 January 2018

1 reference

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

21 January 2018

1 reference

Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells.

21 January 2018

1 reference

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

21 January 2018

1 reference

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway

21 January 2018

1 reference

Pericytes limit tumor cell metastasis

21 January 2018

1 reference

Tumor angiogenesis: molecular pathways and therapeutic targets

21 January 2018

1 reference

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

A causal role for E-cadherin in the transition from adenoma to carcinoma

21 January 2018

1 reference

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth

21 January 2018

1 reference

Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.

21 January 2018

1 reference

A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models

21 January 2018

1 reference

Blocking neuropilin-2 function inhibits tumor cell metastasis

21 January 2018

1 reference

Automated selection of DAB-labeled tissue for immunohistochemical quantification.

21 January 2018

1 reference

Random-effects models for longitudinal data

21 January 2018

1 reference

21 January 2018

1 reference

Loss of Neural Cell Adhesion Molecule Induces Tumor Metastasis by Up-regulating Lymphangiogenesis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PATH.4053

1 reference

24 December 2017

PubMed ID

22611036

1 reference

24 December 2017